244 related articles for article (PubMed ID: 25030058)
1. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.
Papp E; Mohammadi H; Loutfy MR; Yudin MH; Murphy KE; Walmsley SL; Shah R; MacGillivray J; Silverman M; Serghides L
J Infect Dis; 2015 Jan; 211(1):10-8. PubMed ID: 25030058
[TBL] [Abstract][Full Text] [Related]
2. Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.
Papp E; Balogun K; Banko N; Mohammadi H; Loutfy M; Yudin MH; Shah R; MacGillivray J; Murphy KE; Walmsley SL; Silverman M; Serghides L
J Infect Dis; 2016 May; 213(10):1532-40. PubMed ID: 26740274
[TBL] [Abstract][Full Text] [Related]
3. Elevated Levels of Estradiol in Human Immunodeficiency Virus-Infected Pregnant Women on Protease Inhibitor-Based Regimens.
Balogun KA; Guzman Lenis MS; Papp E; Loutfy M; Yudin MH; MacGillivray J; Walmsley SL; Silverman M; Serghides L
Clin Infect Dis; 2018 Jan; 66(3):420-427. PubMed ID: 29020282
[TBL] [Abstract][Full Text] [Related]
4. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
McDonald CR; Conroy AL; Gamble JL; Papp E; Hawkes M; Olwoch P; Natureeba P; Kamya M; Silverman M; Cohan D; Koss CA; Dorsey G; Kain KC; Serghides L
Clin Infect Dis; 2018 Jan; 66(3):428-436. PubMed ID: 29136115
[TBL] [Abstract][Full Text] [Related]
5. Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies.
Kala S; Dunk C; Acosta S; Serghides L
Hum Reprod; 2020 Aug; 35(8):1781-1796. PubMed ID: 32712670
[TBL] [Abstract][Full Text] [Related]
6. Protease inhibitors and adverse birth outcomes: is progesterone the missing piece to the puzzle?
Powis KM; Shapiro RL
J Infect Dis; 2015 Jan; 211(1):4-7. PubMed ID: 25030057
[No Abstract] [Full Text] [Related]
7. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?
Sibiude J; Warszawski J; Tubiana R; Dollfus C; Faye A; Rouzioux C; Teglas JP; Ekoukou D; Blanche S; Mandelbrot L
Clin Infect Dis; 2012 May; 54(9):1348-60. PubMed ID: 22460969
[TBL] [Abstract][Full Text] [Related]
8. Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age.
Snijdewind IJM; Smit C; Godfried MH; Bakker R; Nellen JFJB; Jaddoe VWV; van Leeuwen E; Reiss P; Steegers EAP; van der Ende ME
PLoS One; 2018; 13(1):e0191389. PubMed ID: 29351561
[TBL] [Abstract][Full Text] [Related]
9. Pediatric Neurodevelopmental Functioning After In Utero Exposure to Triple-NRTI vs. Dual-NRTI + PI ART in a Randomized Trial, Botswana.
Kacanek D; Williams PL; Mayondi G; Holding P; Leidner J; Moabi K; Tepper V; Nichols S; Makhema J; Jibril H; Madidimalo T; Shapiro R; Lockman S; Kammerer B
J Acquir Immune Defic Syndr; 2018 Nov; 79(3):e93-e100. PubMed ID: 30015793
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy.
Powis KM; Kitch D; Ogwu A; Hughes MD; Lockman S; Leidner J; van Widenfelt E; Moffat C; Moyo S; Makhema J; Essex M; Shapiro RL
J Infect Dis; 2011 Aug; 204(4):506-14. PubMed ID: 21791651
[TBL] [Abstract][Full Text] [Related]
12. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.
Szyld EG; Warley EM; Freimanis L; Gonin R; Cahn PE; Calvet GA; Duarte G; Melo VH; Read JS;
AIDS; 2006 Nov; 20(18):2345-53. PubMed ID: 17117021
[TBL] [Abstract][Full Text] [Related]
13. HIV antiretroviral exposure in pregnancy induces detrimental placenta vascular changes that are rescued by progesterone supplementation.
Mohammadi H; Papp E; Cahill L; Rennie M; Banko N; Pinnaduwage L; Lee J; Kibschull M; Dunk C; Sled JG; Serghides L
Sci Rep; 2018 Apr; 8(1):6552. PubMed ID: 29700323
[TBL] [Abstract][Full Text] [Related]
14. Adverse fetal and infant outcomes among HIV-infected women who received either nonnucleoside reverse transcriptase inhibitor-based or protease inhibitor-based antiretroviral therapy for prevention of mother-to-child transmission.
Masaba R; Borkowf CB; Girde S; Zeh C; Ndivo R; Nyang'au I; Achola K; Thomas TK; Lecher SL
AIDS; 2018 Jul; 32(12):1625-1632. PubMed ID: 30001243
[TBL] [Abstract][Full Text] [Related]
15. Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy.
Young S; Murray K; Mwesigwa J; Natureeba P; Osterbauer B; Achan J; Arinaitwe E; Clark T; Ades V; Plenty A; Charlebois E; Ruel T; Kamya M; Havlir D; Cohan D
PLoS One; 2012; 7(8):e41934. PubMed ID: 22879899
[TBL] [Abstract][Full Text] [Related]
16. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
Senise JF; Castelo A; Martínez M
AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy during pregnancy and the risk of an adverse outcome.
Tuomala RE; Shapiro DE; Mofenson LM; Bryson Y; Culnane M; Hughes MD; O'Sullivan MJ; Scott G; Stek AM; Wara D; Bulterys M
N Engl J Med; 2002 Jun; 346(24):1863-70. PubMed ID: 12063370
[TBL] [Abstract][Full Text] [Related]
18. Combination antiretroviral use and preterm birth.
Watts DH; Williams PL; Kacanek D; Griner R; Rich K; Hazra R; Mofenson LM; Mendez HA;
J Infect Dis; 2013 Feb; 207(4):612-21. PubMed ID: 23204173
[TBL] [Abstract][Full Text] [Related]
19. Association between maternal human immunodeficiency virus infection and preterm birth: A matched case-control study from a pregnancy outcome registry.
Elenga N; Djossou FÉL; Nacher M
Medicine (Baltimore); 2021 Jan; 100(4):e22670. PubMed ID: 33530154
[TBL] [Abstract][Full Text] [Related]
20. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
